PQ-401

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H16ClN3O2
Molecular Weight	341.792
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(Cl)C=C1NC(=O)NC2=CC(C)=NC3=CC=CC=C23

InChI

InChIKey=YBLWOZUPHDKFOT-UHFFFAOYSA-N

InChI=1S/C18H16ClN3O2/c1-11-9-15(13-5-3-4-6-14(13)20-11)21-18(23)22-16-10-12(19)7-8-17(16)24-2/h3-10H,1-2H3,(H2,20,21,22,23)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25971682
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/21878657 | https://www.ncbi.nlm.nih.gov/pubmed/16648580 | https://www.ncbi.nlm.nih.gov/pubmed/21330367 | https://www.ncbi.nlm.nih.gov/pubmed/21865067 | http://adis.springer.com/drugs/800015134

PQ401 is a diaryl urea compound and a potent inhibitor of autophosphorylation of the IGF-1 receptor. It has been investigated in preclinical studies as a potential cancer treatment in a number of cell models; most notably for breast cancer. It was also studied in mouse models as a possible treatment of diabetic neuropathies, although it showed less promise here.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Insulin-like growth factor 1 receptor 4 Target ID: P08069 Gene ID: 3480.0 Gene Symbol: IGF1R Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16648580	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16648580	Primary		Preclinical	Unknown Approved Use Unknown
Diabetic kidney disease 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21865067	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	2011 Oct 30	22037377
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.	2012 Dec 15	23041229
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	2013 Apr 15	23398362

Patents

Sample Use Guides

In Vivo Use Guide

Female mice [FVB/N-TgN(MMTVneu)202 strain] were injected with MCNeuA tumor cells and treated with PQ401 after 3 days. PQ401 was dissolved into 50% polysorbate 80/50% ethanol and diluted with PBS to a final concentration of 4 mg/mL. Treated mice received 50 or 100 mg/kg PQ401 three times a week as an intraperitoneal injection. Tumor growth was reduced by 20% in mice treated with 100 mg/kg relative to control mice.

Route of Administration: Intraperitoneal

In Vitro Use Guide

Human MCF-7 breast cancer cells were incubated with 1.5, 7.5, 15 and 30 micromol/L PQ401 for for 1 hour. Cells were then incubated ± 3 nmol/L IGF-I. Autophosphorylation of IGF-IR was determined from soluble extracts by specific ELISA, and PQ401 was found to have an IC50 of 12 ± 0.9 microM.

Name

Type

Language

PQ-401

Common Name

English

UREA, N-(5-CHLORO-2-METHOXYPHENYL)-N'-(2-METHYL-4-QUINOLINYL)-

Systematic Name

English

N-(5-CHLORO-2-METHOXYPHENYL)-N'-(2-METHYL-4-QUINOLINYL)UREA

Systematic Name

English

Code System Code Type Description

CAS

1184297-34-4